• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Rosuvastatin Calcium

Rosuvastatin Calcium

Product ID R5974
Cas No. 147098-20-2
Purity ≥98%
Product Unit SizeCostQuantityStock
25 mg $169.10 In stock
100 mg $563.60 In stock
250 mg $1,070.70 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Rosuvastatin is an inhibitor of HMG-CoA reductase that decreases serum LDL and VLDL and is used to treat atherosclerosis in clinical settings. In addition to anti-atherosclerotic benefit, rosuvastatin also exhibits anti-inflammatory, cardioprotective, and anti-platelet activities. In animal models, rosuvastatin decreases levels of plasma lipids and angiotensin II (ATII) by inhibiting expression of the angiotensin II type 1 (AT1) receptor and p-ERK1/2 and upregulating scavenger receptor B1. Separately, rosuvastatin downregulates ERK, p38MAPK, matrix metalloproteinases 2 and 9 (MMP2/9), and PAI expression, inhibiting migration and proliferation of vascular smooth muscle cells. This compound also downregulates expression of the nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome, inhibiting cardiac remodeling and dysfunction in animal models of diabetic cardiomyopathy. Additionally, rosuvastatin inhibits activation of NADPH oxidase and PKC, decreasing platelet recruitment and activation in vitro and ex vivo.

Product Info

Cas No.

147098-20-2

Purity

≥98%

Formula

2C22H28FN3O6S) Ca2+

Formula Wt.

1001.14

Chemical Name

(S-((R*,S*-(E)))- 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2- (methyl(methylsulfonyl) amino)-5-pyrimidinyl)-3,5-dihydroxy- 6-heptenoic acid, calcium salt (2:1)

IUPAC Name

calcium;(E,3R, 5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2- ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate

Melting Point

156-160°C dec°mp

Solubility

Slightly soluble in water, marginally soluble in ethanol,soluble in DMSO(100mg/mL), DMF

Appearance

White to yellow powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

R5974 MSDS PDF

Info Sheet

R5974 Info Sheet PDF

Brochure

Statins Flyer

References

Li Y, Wang Q, Zhou J, et al. Rosuvastatin attenuates atherosclerosis in rats via activation of scavenger receptor class B type I. Eur J Pharmacol. 2013 Dec 10;723C:23-28. [Epub ahead of print]. PMID: 24333476.

Luo B, Li B, Wang W, et al. Rosuvastatin Alleviates Diabetic Cardiomyopathy by Inhibiting NLRP3 Inflammasome and MAPK Pathways in a Type 2 Diabetes Rat Model. Cardiovasc Drugs Ther. 2013 Nov 20. [Epub ahead of print]. PMID: 24254031.

Gan J, Li P, Wang Z, et al. Rosuvastatin suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway. Exp Ther Med. 2013 Oct;6(4):899-903. PMID: 24137286.

Hu X, Sun A, Xie X, et al. Rosuvastatin changes cytokine expressions in ischemic territory and preserves heart function after acute myocardial infarction in rats. J Cardiovasc Pharmacol Ther. 2013 Mar;18(2):162-76. PMID: 23139358.

Pignatelli P, Carnevale R, Di Santo S, et al. Rosuvastatin reduces platelet recruitment by inhibiting NADPH oxidase activation. Biochem Pharmacol. 2012 Dec 15;84(12):1635-42. PMID: 23022230.

Laumen H, Skurk T, Hauner H. The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis. 2008 Feb;196(2):565-73. PMID: 17692320.

Holdgate GA, Ward WH, McTaggart F. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans. 2003 Jun;31(Pt 3):528-31. PMID: 12773150.

Izumi S, Nozaki Y, Maeda K, et al. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions. Drug Metab Dispos. 2015 Feb;43(2):235-247. PMID: 25414411.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • G5875

    Gossypol Acetic Acid

    Bcl-2, Bcl-xl, sialyl transferase inhibitor.

    ≥98%
  • O1177

    n-Octyl-3,4-Dimethylcaffeate

    Methylated derivative of n-octyl-caffeate.

    ≥98%
  • T6931

    Triclosan

    Diarylether; bacterial ENR binder, fatty acid s...

    ≥98%
  • B3209

    Bicalutamide

    AR antagonist.

    ≥98%
  • S0400

    SB-431542

    ALK4/5/7 (activin-like) inhibitor, TGF-β inhib...

    ≥98%
  • P8117

    Puerarin, High Purity

    Isoflavone found in Pueraria; 5-HT2C and GABA-A...

    ≥99%
  • S6131

    N,N-Dimethyl-Sphingosine

    PP2A activator, Sphk1 and PKC inhibitor.

    ≥98%
  • C9612

    Cyclosporin C

    Cyclosporin metabolite; weak calmodulin inhibit...

    ≥98%
  • D3420

    4-(3,4-Difluorobenzo)curcumin

    Curcumin derivative.

    ≥95%
  • A480000

    AM251

    CB1 receptor antagonist/ inverse agonist.

    ≥97%
  • T0100

    10-Deacetyltaxol

    Taxane found in Taxus; microtubule depolymeriza...

    ≥98%
  • K040009

    KB-0742 dihydrochloride

    CDK9 inhibitor.

    ≥99%
  • P0092

    Paclitaxel, from Taxus yunnanensis

    Diterpene found in Taxus yunnanensis; microtubu...

    ≥98%
  • T1953

    Tenovin-3

    Potential p53 activator or SIRT2 inhibitor.

    ≥98%
  • P7718

    Pterostilbene

    Stilbene, resveratrol analog.

    ≥98%
  • M1677

    11-Methoxyyangonin

    Minor kavalactone originally found in Piper met...

    ≥98%
  • T3035

    Thienylheptyl Isothiocyanate

    Thienylbutyl ITC analog.

    ≥95%
  • R2815

    Recombinant HIV-1 “0” group consensus

    Recombinant HIV-1 antigen fragment.

    ≥95%
  • S0253

    Sanguinarine

    Benzophenanthridine alkaloid found in various p...

    ≥98%
  • P3313

    Pidotimod

    Immunostimulator, adjuvant.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only